I got in largely in part from similarities to AMBS from a couple of years ago when it went from .004 to .16... but, you don't get duplicate opportunities. assets versus liabilities were similar, relatively speaking, shares outstanding versus shares authorized ratio also similar, similar oversold charts, biomedical/biotech fields, unique product offerings, both a history of promos, current reporting.. big differences though that AMBS was much more involved with the press at the time, maintained their website, was more of a unique bioscience related co. than biotechnology product co., way more involved with marketing, way more transparent. however, they were also diluting extremely heavily at the time. CBAT has unique technology and could drop a couple of bomb PRs at any time, either a product trials update or a funding arrangement, or another promo since they have a history of them...
CorLink&CorView:
99% complete
The cloud system is 98% complete, as the mechanism for sending and receiving studies is implemented with email notification along with the User management and security protocols. The mobile application is also 99-100% complete allowing for users to capture, analyze, process, manage and send 12 lead high resolution ECGs.
Cost to completion between $5,000 and $30,000 for FDA approvals and medical trials. This amount does not include marketing or sales costs which are not yet determined. For the purposes of our funding requirements we have used $30,000 for completion costs, but have not impacted any marketing or sales costs as those will be determined once the medical trials and FDA approvals have been received.
CorTab:
99% complete
From the date of acquisition of the project the Company has migrated from an embedded ECG solution to a Bluetooth based solution through the R&D process. A prototype, fully functional Unit is being tested at the moment on patients. The advanced tablet prototype was received from our manufacturer in China. The Bluetooth patient acquisition module was, manufactured and assembled in-house at the Cortronix headquarters. Arrangements have been made to begin production once orders are received.
During September 2013 the prototype for CorTab was received and tested and is mostly functional, ready for trials.
Testing costs fall within the Corview costs, defined above and the product will require FDA approvals and medical trials
